Therapeuticsmd Inc (NASDAQ:TXMD) Shorted Shares Decreased By 1.72%

June 27, 2018 - By Rebecca Betts

TherapeuticsMD, Inc. (NASDAQ:TXMD) Corporate Logo

Big Money Sentiment decreased to 1.47 in Q1 2018. It has change of 0.15, from 2017Q4’s 1.62. The ratio turned negative due to TherapeuticsMD, Inc. positioning: 17 sold and 28 reduced. 21 funds bought positions and 45 increased positions. Investors holded 159.91 million in 2017Q4 but now own 160.49 million shares or 0.36% more.
Raymond James & Associates invested 0% in TherapeuticsMD, Inc. (NASDAQ:TXMD). Sg Americas Limited Liability Corp reported 20,164 shs. United Svcs Automobile Association invested 0% in TherapeuticsMD, Inc. (NASDAQ:TXMD). Zeke Capital Advsrs Ltd Liability Co stated it has 0% of its capital in TherapeuticsMD, Inc. (NASDAQ:TXMD). Ameritas Investment Prns invested 0% of its capital in TherapeuticsMD, Inc. (NASDAQ:TXMD). Zurcher Kantonalbank (Zurich Cantonalbank) accumulated 0% or 7,336 shs. International Group Inc Inc holds 0% or 105,897 shs in its capital. Beaumont Fincl Partners Ltd Company reported 25,300 shs. Oppenheimer & Communication Incorporated holds 0.01% or 69,129 shs. Northern Tru holds 0% of its capital in TherapeuticsMD, Inc. (NASDAQ:TXMD) for 2.01M shs. Maryland-based Proshare Advisors Ltd Com has invested 0% in TherapeuticsMD, Inc. (NASDAQ:TXMD). Ny State Common Retirement Fund holds 255,339 shs. Rock Springs Cap Lp has invested 0.24% of its capital in TherapeuticsMD, Inc. (NASDAQ:TXMD). Huntington Comml Bank owns 6,000 shs or 0% of their US capital. Moreover, Hanson Mcclain has 0% invested in TherapeuticsMD, Inc. (NASDAQ:TXMD) for 500 shs.

Therapeuticsmd Inc (NASDAQ:TXMD) showed a decrease of 1.72% in shorted shares. FINRA announced in June TXMD’s total 57.53M shorted shares. That’s 1.72% down from 58.53 million shares. Former TXMD’s position will need 31 days to recover. It has 1.84 million average volume. Therapeuticsmd Inc’s shorted shares float is 33.42%.

The stock decreased 1.72% or $0.12 during the last trading session, hitting $6.87.Currently TherapeuticsMD, Inc. is uptrending after 49.88% change in last June 27, 2017. TXMD has also 348,937 shares volume. TXMD outperformed the S&P 500 by 37.31%.

TherapeuticsMD, Inc. operates as a women??s health care product company.The firm is worth $1.49 billion. The firm makes and distributes prescription and over-the-counter product lines, including prenatal vitamins, iron supplements, and natural menopause relief products under the vitaMedMD brand, as well as generic formulations of its prescription prenatal vitamins products under the BocaGreenMD Prena1 name.Currently it has negative earnings. The Company’s pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen.

There’s a substantial TherapeuticsMD, Inc. (NASDAQ:TXMD) news published by Nasdaq.com. It’s a report titled: “Here’s Why TherapeuticsMD Inc Jumped Today” on June 05, 2018.

TherapeuticsMD, Inc. (NASDAQ:TXMD) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: